This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:—
Orally given methyltestosterone has been used in clinical practice since its introduction by Foss in 1939 (Brit. M. J.2:11, 1939) both for its anabolic and for its androgen effects. It was not until 1947 that Werner (Am. J. Med.3:52, 1947) suggested that its use might rarely be associated with jaundice. Other reports followed (Kinsell, L. W.: Gastroenterology11:672, 1948; Werner, S. C.; Hanger, F. M.; and Kritzler, R. A.: Am. J. Med.8:325, 1950; Wood, J. C.: J. A. M. A.150:1484-1486 [Dec. 13] 1952; Van Dommelen, C. K. V., and Van der Steur, J. C.: Nederl. tijdschr. geneesk.99:2732, 1955; Brick, I. B., and Kyle, L. H.: New England J. Med.246:176, 1952). According to Werner and co-workers (ibid.) the whole picture of jaundice associated with methyltestosterone seems to be due to bile stasis. Biopsy showed dilated
Foss GL, Simpson SL. METHYLATED STEROIDS AND JAUNDICE. JAMA. 1957;164(4):486. doi:10.1001/jama.1957.02980040126027
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: